Author: Editor

Editor represents multiple online news sites, including STL.News, RSSNews.Press and more. We believe that our "direct source news" concept helps provide accurate information to the public without bias. We want to help improve technology so the news is presented as it was intended to be.

NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)

GSK reiterates commitment to 12 week free access programme NICE today issued its final appraisal determinationadvising against NHS funding for…

Continue Reading NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)

GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)

Issued: Tuesday 17 February 2009, London UK GlaxoSmithKline today announced initiation and dosing of the first patient of the Phase…

Continue Reading GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)

Results announcement for the fourth quarter 2008

See the quarterly results page for more information. Source link

Continue Reading Results announcement for the fourth quarter 2008

GlaxoSmithKline plc, announces board changes

Issued: Monday 2 February 2009, London UK GlaxoSmithKline plc (GSK) announces that Mr. James Murdoch has been appointed as a…

Continue Reading GlaxoSmithKline plc, announces board changes

Deirdre Connelly to join GSK as President, North American Pharmaceuticals

Issued: Friday 30 January 2009, London, UK & Philadelphia, US GlaxoSmithKline (GSK) today announced that Deirdre Connelly will join the…

Continue Reading Deirdre Connelly to join GSK as President, North American Pharmaceuticals

GSK announces charges for legal matters

Issued: Thursday 29 January 2009, London, UK & Philadelphia, US GlaxoSmithKline plc (GSK) today announced that it will record a…

Continue Reading GSK announces charges for legal matters

The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®

– The UK is now one of the world’s leading countries in stockpiling antivirals for treating infected individuals in the…

Continue Reading The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®

GSK to drive growth in emerging markets with acquisition of UCB products

Issued:  Friday 23 January 2009, London UK GlaxoSmithKline plc (GSK) today announced that it has signed an agreement with UCB…

Continue Reading GSK to drive growth in emerging markets with acquisition of UCB products

GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe

Serotypes included in the vaccine are responsible for up to 90% of invasive pneumoccal disease in young children in Europe….

Continue Reading GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe

GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)

Issued: Wednesday 21 January 2009, London UK A decision made by the European Commission today opens access to a treatment…

Continue Reading GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)

GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome

Issued:  Friday 9 January 2009, London, UK, Research Triangle Park, NC & Santa Clara, CA GlaxoSmithKline and XenoPort, Inc. announced…

Continue Reading GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome